Non-severe burn injury increases cancer incidence in mice and has long-term impacts on the activation and function of T cells

Abstract

Background: Recent evidence suggests that burn patients are at increased risk of hospital admission for infection, mental health conditions, cardiovascular disease and cancer for many years after discharge for the burn injury itself. Burn injury has also been shown to induce sustained immune system dysfunction. This change to immune function may contribute to the increased risk of chronic disease observed. However, the mechanisms that disrupt long-term immune function in response to burn trauma, and their link to long-term morbidity, remain unknown. In this study we investigated changes to immune function after burn injury using a murine model of non-severe injury. Methods: An established mouse model of non-severe burn injury (full thickness burn equivalent to 8% total body surface area) was used in combination with an orthotopic model of B16 melanoma to investigate the link between burns and cancer. Considering that CD8⁺ T cells are important drivers of effective tumour suppression in this model, we also investigated potential dysregulation of this immune population using mouse models of burn injury in combination with herpes simplex virus infection. Flow cytometry was used to detect and quantify cell populations of interest and changes in immune function. Results: We demonstrate that 4 weeks after a non-severe burn injury, mice were significantly more susceptible to tumour development than controls using an orthotopic model of B16 melanoma. In addition, our results reveal that CD8⁺ T cell expansion, differentiation and memory potential is significantly impaired at 1 month post-burn. Conclusions: Our data suggests that CD8⁺ T cell-mediated immunity may be dysfunctional for a sustained period after even non-severe burn injury. Further studies in patients to validate these findings may support clinical intervention to restore or protect immunity in patients after burn injury and reduce the increased risk of secondary morbidities observed.

Keywords

Immunology / Surgery / Burn injury / T cells / Immune dysfunction / Cancer

References

[1] Barrett LW, Fear VS, Waithman JC, Wood FM, Fear MW. Understanding acute burn injury as a chronic disease. Burns Trauma. 2019; 7: 23. https://doi.org/10.1186/s41038-019-0163-2.

[2] Randall SM, Fear MW, Wood FM, Rea S, Boyd JH, Duke JM. Long-term musculoskeletal morbidity after adult burn injury: a population-based cohort study. BMJ Open. 2015; 5: e009395. https://doi.org/10.1136/bmjopen-2015-009395.

[3] Vetrichevvel TP, Randall SM, Fear MW, Wood FM, Boyd JH, Duke JM. Burn injury and long-term nervous system morbidity: a population-based cohort study. BMJ Open. 2016; 6:e012668. https://doi.org/10.1136/bmjopen-2016-012668.

[4] Stevenson AW, Randall SM, Boyd JH, Wood FM, Fear MW, Duke JM. Burn leads to long-term elevated admissions to hospital for gastrointestinal disease in a west Australian population based study. Burns. 2017; 43: 665-73.

[5] Duke JM, Randall SM, Fear MW, Boyd JH, Rea S, Wood FM. Understanding the long-term impacts of burn on the cardiovascular system. Burns. 2016; 42: 366-74.

[6] Fear VS, Boyd JH, Rea S, Wood FM, Duke JM, Fear MW. Burn injury leads to increased long-term susceptibility to respiratory infection in both mouse models and population studies. PLoS One. 2017; 12: e0169302. https://doi.org/10.1371/journal.pone.0169302.

[7] Duke J, Rea S, Semmens J, Edgar DW, Wood F. Burn and cancer risk: a state-wide longitudinal analysis. Burns. 2012; 38: 340-7.

[8] Duke JM, Randall SM, Wood FM, Boyd JH, Fear MW. Burns and long-term infectious disease morbidity: a population-based study. Burns. 2017; 43: 273-81.

[9] Duke J, Wood F, Semmens J, Spilsbury K, Edgar DW, Hendrie D, et al. A 26-year population-based study of burn injury hospital admissions in Western Australia. J Burn Care Res. 2011; 32: 379-86.

[10] Duke JM, Rea S, Boyd JH, Randall SM, Wood FM. Mortality after burn injury in children: a 33-year population-based study. Pediatrics. 2015; 135: e903-10. https://doi.org/10.1542/peds.2014-3140.

[11] Jeschke MG, Gauglitz GG, Kulp GA, Finnerty CC, Williams FN, Kraft R, et al. Long-term persistance of the pathophysiologic response to severe burn injury. PLoS One. 2011; 6: e21245. https://doi.org/10.1371/journal.pone.0021245.

[12] Johnson BZ, McAlister S, McGuire HM, Palanivelu V, Stevenson A, Richmond P, et al. Pediatric burn survivors have long-term immune dysfunction with diminished vaccine response. Front Immunol. 2020; 11: 1481. https://doi.org/10.3389/fimmu.2020.01481.

[13] Duke JM, Randall SM, Fear MW, Boyd JH, Rea S, Wood FM. Respiratory morbidity after childhood burns: a 10-year follow-up study. Pediatrics. 2016; 138: e20161658. https://doi.org/10.1542/peds.2016-1658.

[14] Finn OJ. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Ann Oncol. 2012; 23 Suppl 8: viii6-9. https://doi.org/10.1093/annonc/mds256.

[15] Giles N, Rea S, Beer T, Wood FM, Fear MW. A peptide inhibitor of c-Jun promotes wound healing in a mouse full-thickness burn model. Wound Repair Regen. 2008; 16: 58-64.

[16] Wylie B, Seppanen E, Xiao K, Zemek R, Zanker D, Prato S, et al. Cross-presentation of cutaneous melanoma antigen by migratory XCR1⁺CD103⁻ and XCR1⁺CD103⁺ dendritic cells. Oncoimmunology. 2015; 4:e1019198. https://doi.org/10.1080/2162402X.2015.1019198.

[17] Park SL, Buzzai A, Rautela J, Hor JL, Hochheiser K, Effern M, et al. Tissue-resident memory CD8⁺ T cells promote melanoma-immune equilibrium in skin. Nature. 2019; 565: 366-71.

[18] Duke JM, Bauer J, Fear MW, Rea S, Wood FM, Boyd J. Burn injury, gender and cancer risk: population-based cohort study using data from Scotland and Western Australia. BMJ Open. 2014; 4: e003845. https://doi.org/10.1136/bmjopen-2013-003845.

[19] Duke JM, Boyd JH, Randall SM, Wood FM. Long term mortality in a population-based cohort of adolescents, and young and middle-aged adults with burn injury in Western Australia: a 33-year study. Accid Anal Prev. 2015; 85: 118-24.

[20] Mueller SN, Heath W, McLain JD, Carbone FR, Jones CM. Characterization of two TCR transgenic mouse lines specific for herpes simplex virus. Immunol Cell Biol. 2002; 80: 156-63.

[21] Bedoui S, Greyer M. The role of dendritic cells in immunity against primary herpes simplex virus infections. Front Microbiol. 2014; 5: 533. https://doi.org/10.3389/fmicb.2014.00533.

[22] van Lint A, Ayers M, Brooks AG, Coles RM, Heath WR, Carbone FR. Herpes simplex virus-specific CD8+ T cells can clear established lytic infections from skin and nerves and can partially limit the early spread of virus after cutaneous inoculation. J Immunol. 2004; 172: 392-7.

[23] Coles RM, Mueller SN, Heath WR, Carbone FR, Brooks AG. Progression of armed CTL from draining lymph node to spleen shortly after localized infection with herpes simplex virus 1. J Immunol. 2002; 168: 834-8.

[24] Bedoui S, Whitney PG, Waithman J, Eidsmo L, Wakim L, Caminschi I, et al. Cross-presentation of viral and self antigens by skin-derived CD103+ dendritic cells. Nat Immunol. 2009; 10: 488-95.

[25] Samuel CE. Antiviral actions of interferons. Clin Microbiol Rev. 2001; 14: 778-809 table of contents.

[26] Boyman O, Cho JH, Sprent J. The role of interleukin-2 in memory CD8 cell differentiation. Adv Exp Med Biol. 2010; 684: 28-41.

[27] Nowacki TM, Kuerten S, Zhang W, Shive CL, Kreher CR, Boehm BO, et al. Granzyme B production distinguishes recently activated CD8(+) memory cells from resting memory cells. Cell Immunol. 2007; 247: 36-48.

[28] Curtsinger JM, Lins DC, Johnson CM, Mescher MF. Signal 3 tolerant CD8 T cells degranulate in response to antigen but lack granzyme B to mediate cytolysis. J Immunol. 2005; 175: 4392-9.

[29] Martin MD, Badovinac VP. Defining memory CD8 T cell. Front Immunol. 2018; 9: 2692. https://doi.org/10.3389/fimmu.2018.02692.

[30] Gebhardt T, Palendira U, Tscharke DC, Bedoui S. Tissue-resident memory T cells in tissue homeostasis, persistent infection, and cancer surveillance. Immunol Rev. 2018; 283: 54-76.

[31] Amsen D, van Gisbergen KPJM, Hombrink P, van Lier RAW. Tissue-resident memory T cells at the center of immunity to solid tumors. Nat Immunol. 2018; 19: 538-46.

[32] Blair DA, Turner DL, Bose TO, Pham QM, Bouchard KR, Williams KJ, et al. Duration of antigen availability influences the expansion and memory differentiation of T cells. J Immunol. 2011; 187: 2310-21.

[33] van de Ven K, Borst J. Targeting the T-cell co-stimulatory CD27/CD70 pathway in cancer immunotherapy: rationale and potential. Immunotherapy. 2015; 7: 655-67.

[34] Hendriks J, Gravestein LA, Tesselaar K, van Lier RA, Schumacher TN, Borst J. CD27 is required for generation and long-term maintenance of T cell immunity. Nat Immunol. 2000; 1: 433-40.

[35] Bourque J, Hawiger D. Immunomodulatory bonds of the partnership between dendritic cells and T cells. Crit Rev Immunol. 2018; 38: 379-401.

[36] Kawamura T, Ogawa Y, Shimozato O, Ando T, Nakao A, Kobata T, et al. CD70 is selectively expressed on Th1 but not on Th2 cells and is required for Th1-type immune responses. J Invest Dermatol. 2011; 131: 1252-61.

[37] Peperzak V, Xiao Y, Veraar EA, Borst J. CD27 sustains survival of CTLs in virus-infected nonlymphoid tissue in mice by inducing autocrine IL-2 production. J Clin Invest. 2010; 120: 168-78.

[38] Welten SPM, Yermanos A, Baumann NS, Wagen F, Oetiker N, Sandu I, et al. Tcf1⁺ cells are required to maintain the inflationary T cell pool upon MCMV infection. Nat Commun. 2020; 11: 2295. https://doi.org/10.1038/s41467-020-16219-3.

[39] Ahrends T, Spanjaard A, Pilzecker B, Bąbała N, Bovens A, Xiao Y, et al. CD4⁺ T cell help confers a cytotoxic T cell effector program including Coinhibitory receptor downregulation and increased tissue invasiveness. Immunity. 2017; 47: 848-861.e5.

[40] Ahrends T, Busselaar J, Severson TM, Bąbała N, de Vries E, Bovens A, et al. CD4⁺ T cell help creates memory CD8⁺ T cells with innate and help-independent recall capacities. Nat Commun. 2019; 10: 5531. https://doi.org/10.1038/s41467-019-13438-1.